187 related articles for article (PubMed ID: 33787071)
1. Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma.
Eso Y; Nakano S; Mishima M; Arasawa S; Iguchi E; Takeda H; Takai A; Takahashi K; Taura K; Seno H
J Hepatobiliary Pancreat Sci; 2021 Jun; 28(6):498-507. PubMed ID: 33787071
[TBL] [Abstract][Full Text] [Related]
2. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
[TBL] [Abstract][Full Text] [Related]
3. Branched-chain amino acid to tyrosine ratio is an essential pre-treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma.
Eso Y; Nakano S; Mishima M; Arasawa S; Iguchi E; Takeda H; Takai A; Takahashi K; Seno H
J Hepatobiliary Pancreat Sci; 2020 Dec; 27(12):913-921. PubMed ID: 32894808
[TBL] [Abstract][Full Text] [Related]
4. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients.
Mak LY; To WP; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
World J Gastroenterol; 2019 Mar; 25(11):1398-1408. PubMed ID: 30918432
[TBL] [Abstract][Full Text] [Related]
5. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
Takahashi A; Moriguchi M; Seko Y; Ishikawa H; Yo T; Kimura H; Fujii H; Shima T; Mitsumoto Y; Ishiba H; Takashima H; Nagao Y; Jo M; Arai M; Hara T; Okajima A; Muramatsu A; Morita A; Yoshinami N; Nakajima T; Mitsuyoshi H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y
Anticancer Res; 2019 Sep; 39(9):5149-5156. PubMed ID: 31519627
[TBL] [Abstract][Full Text] [Related]
6. On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy.
Murata A; Amano N; Sato S; Tsuzura H; Tomishima K; Sato S; Matsumoto K; Shimada Y; Iijima K; Genda T
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192084
[TBL] [Abstract][Full Text] [Related]
7. Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis.
Su TH; Peng CY; Tseng TC; Yang HC; Liu CJ; Liu CH; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2020 Feb; 221(4):589-597. PubMed ID: 31574141
[TBL] [Abstract][Full Text] [Related]
8. Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma.
Okubo H; Ando H; Ishizuka K; Kitagawa R; Okubo S; Saito H; Kokubu S; Miyazaki A; Ikejima K; Shiina S; Nagahara A
PLoS One; 2020; 15(3):e0229772. PubMed ID: 32126131
[TBL] [Abstract][Full Text] [Related]
9. Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma.
Yamaoka K; Kodama K; Hiramatsu A; Ando Y; Kosaka Y; Suehiro Y; Fujii Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Miki D; Tsuge M; Imamura M; Takahashi S; Chayama K; Aikata H
J Gastroenterol Hepatol; 2021 Jun; 36(6):1685-1693. PubMed ID: 33326154
[TBL] [Abstract][Full Text] [Related]
10. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
11. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y
J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305
[TBL] [Abstract][Full Text] [Related]
12. Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study.
Kinoshita A; Hagiwara N; Osawa A; Akasu T; Matsumoto Y; Ueda K; Saeki C; Oikawa T; Koike K; Saruta M
J Oncol Pharm Pract; 2023 Apr; 29(3):626-636. PubMed ID: 35112972
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
14. The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma.
Kinoshita A; Hagiwara N; Osawa A; Akasu T; Matsumoto Y; Ueda K; Saeki C; Oikawa T; Koike K; Saruta M
In Vivo; 2022; 36(2):865-873. PubMed ID: 35241544
[TBL] [Abstract][Full Text] [Related]
15. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.
Hata K; Suetsugu K; Egashira N; Makihara Y; Itoh S; Yoshizumi T; Tanaka M; Kohjima M; Watanabe H; Masuda S; Ieiri I
Cancer Chemother Pharmacol; 2020 Dec; 86(6):803-813. PubMed ID: 33095285
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.
Obi S; Sato T; Sato S; Kanda M; Tokudome Y; Kojima Y; Suzuki Y; Hosoda K; Kawai T; Kondo Y; Isomura Y; Ohyama H; Nakagomi K; Ashizawa H; Miura Y; Amano H; Mochizuki H; Omata M
Hepatol Int; 2019 Mar; 13(2):199-204. PubMed ID: 30671808
[TBL] [Abstract][Full Text] [Related]
18. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
20. Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Yuruki H; Motohara T; Chiyonaga S; Akahoshi S
Anticancer Res; 2019 Dec; 39(12):6895-6901. PubMed ID: 31810959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
